What is BioSensics?
Founded in 2007 by three Harvard scientists, BioSensics has emerged as a global leader in the creation of wearable medical devices and digital health technologies. The company specializes in robust digital health data collection and precise measurement of disease symptoms, with a particular focus on novel technologies and validated biomarkers for neurological and rare disorders. BioSensics has been instrumental in integrating wearable sensor technology into healthcare and clinical research, offering validated solutions for enhanced patient monitoring and health assessment.
How much funding has BioSensics raised?
BioSensics has raised a total of $2.9M across 2 funding rounds:
Grant
$2.5M
Debt
$350K
Grant (2017): $2.5M with participation from National Institutes of Health
Debt (2020): $350K led by PPP
Key Investors in BioSensics
National Institutes of Health
The National Institutes of Health (NIH) is a U.S. government agency dedicated to biomedical and health-related research, providing significant grant funding to advance scientific discovery and public health initiatives.
PPP
Public-Private Partnership
What's next for BioSensics?
The recent major strategic investment signals a new phase of growth and innovation for BioSensics. This capital infusion is expected to accelerate the development and deployment of their advanced digital health technologies, potentially expanding their reach in clinical trials and patient monitoring for neurological and rare disorders. The company's strong foundation in research and its established track record suggest a strategic focus on further validating biomarkers and enhancing the precision of their wearable devices, positioning them for continued leadership in the digital health landscape.
See full BioSensics company page
